Epinephrine HFA-MDI (E004) + Placebo-HFA
Phase 3Completed 0 watching 0 views this week๐ Rising
72
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Asthma
Conditions
Asthma
Trial Timeline
Oct 1, 2012 โ Dec 1, 2013
NCT ID
NCT01737905About Epinephrine HFA-MDI (E004) + Placebo-HFA
Epinephrine HFA-MDI (E004) + Placebo-HFA is a phase 3 stage product being developed by Amphastar Pharmaceuticals for Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT01737905. Target conditions include Asthma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01737905 | Phase 3 | Completed |
Competing Products
20 competing products in Asthma
Other Products from Amphastar Pharmaceuticals
E004 (Epinephrine Inhalation Aerosol) HFA-MDI + Placebo-HFAPhase 3
72
albuterol (Armstrong Albuterol HFA) + Albuterol Sulfate (Provenetil-HFA) + Placebo-HFAPhase 3
72
Placebo + Primatene Mist + Epinephrine inhalationPhase 3
72
Armstrong Albuterol Sulfate Inhalation Aerosol + Albuterol Sulfate Inhalation AerosolPhase 3
72
albuterol HFA (Armstrong's) + albuterol HFA (Proventil HFA) + HFA placeboPhase 3
72